blobid3.png

 

 

CSL Seqirus wishes to advise that Q-VAX® vaccine will change to a vial presentation, from June 2026* to support continuity of supply

 

*Please note that the transition timelines will vary and will be subject to exhaustion of current pre-filled syringe supplies. Please also note that the current presentation may still be in use in the market and remains acceptable to use where appropriate, despite the upcoming update for the Q-VAX® vaccine.

 

This change relates only to the vaccine presentation.

 

Please note, there is no change in the vaccine pre-screening process, formulation, dose, indication, route of administration (subcutaneous)

 

Current Presentation New Presentation

Q-VAX® Q Fever Vaccine pre-filled syringe (PFS) ≥25 microgram/0.5mL dose

 

 

Current Presentation

(from June 2026 onwards*)

Q-VAX® Q FEVER VACCINE VIAL
≥25 microgram/0.5mL dose 

 

New Material No: 10056123

 

NB: Syringe/needle not provided

New Presentation

 

To ensure continuity and consistency of supply, we ask that you update your systems accordingly.

 

To reduce risk of vaccine and skin test selection error:

  • Please note that the vaccine vial carton, label & cap colour is different to Skin Test vial carton, label & cap colour
Skin Test Vital Vaccine Vial - New

Carton Colour - Blue

Vial Label Colour - White

Vial Cap Colour - Green

Current Presentation

Carton Colour - Green

Vial Label Colour - Green

Vial Cap Colour - Red

New Presentation

 

Why is this change occurring? 

 

The change to a vial presentation is a medium-term measure to support continuity of supply.

 

CSL Seqirus anticipates a return to the pre-filled syringe presentation in the future, subject to manufacturing and regulatory considerations.

 

 

For further enquiries